PureTech Health plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRTC.L research report →
Companywww.puretechhealth.com
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs.
- CEO
- Robert Lyne
- IPO
- 2015
- Employees
- 80
- HQ
- Boston, MA, US
Price Chart
Valuation
- Market Cap
- $318.88M
- P/E
- -0.38
- P/S
- 90.34
- P/B
- 0.13
- EV/EBITDA
- -1.95
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -471.15%
- Op Margin
- -2115.41%
- Net Margin
- -2355.50%
- ROE
- -31.83%
- ROIC
- -19.63%
Growth & Income
- Revenue
- $4.76M · 10.24%
- Net Income
- $-112,041,357 · -309.38%
- EPS
- $-0.47 · -335.00%
- Op Income
- $-100,592,083
- FCF YoY
- 35.32%
Performance & Tape
- 52W High
- $148.00
- 52W Low
- $104.71
- 50D MA
- $123.76
- 200D MA
- $126.43
- Beta
- 0.79
- Avg Volume
- 621.74K
Get TickerSpark's AI analysis on PRTC.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PRTC.L Coverage
We haven't published any research on PRTC.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PRTC.L Report →